Design, synthesis and pharmacological evaluation of HIV-1 reverse transcriptase inhibition of new indolin-2-ones

Medicinal Chemistry

Volumn 3, Issue 6, 2007, Pages 533-542

  Boechat, Núbia ^a   Kover, W Bruce ^b   Bongertz, Vera ^a   Bastos, Mônica M ^a,b   Romeiro, Nelilma C ^a   Azevedo, Maria L G ^a   Wollinger, Wagner ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Efavirenz; Isatins; Molecular modeling

Indexed keywords

2,3 BIS(2 CYCLOPROPYLETHYNYL) 1 METHYLINDOLINE 2,3 DIOL; 2,3 BIS(2 CYCLOPROPYLETHYNYL) 1,5 DIMETHYLINDOLINE 2,3 DIOL; 3 (2 CYCLOPROPYLETHYNYL) 3 HYDROXY 1 METHYLINDOLIN 2 ONE; 3 (2 CYCLOPROPYLETHYNYL) 3 HYDROXY 1,5 DIMETHYLINDOLIN 2 ONE; 3 (2 CYCLOPROPYLETHYNYL) 3 HYDROXY 5 METHYLINDOLIN 2 ONE; 3 (2 CYCLOPROPYLETHYNYL) 3 HYDROXYINDOLIN 2 ONE; 3 (2 CYCLOPROPYLETHYNYL) 3 HYDROXYINDOLIN 2 ONE DERIVATIVE; 5 BROMO 2,3 BIS(2 CYCLOPROPYLETHYNYL) 1 METHYLINDOLINE 2,3 DIOL; 5 BROMO 3 (2 CYCLOPROPYLETHYNYL) 3 HYDROXY 1 METHYLINDOLIN 2 ONE; 5 BROMO 3 (2 CYCLOPROPYLETHYNYL) 3 HYDROXYINDOLIN 2 ONE; 5 CHLORO 2,3 BIS(2 CYCLOPROPYLETHYNYL) 1 METHYLINDOLINE 2,3 DIOL; 5 CHLORO 3 (2 CYCLOPROPYLETHYNYL) 3 HYDROXY 1 METHYLINDOLIN 2 ONE; 5 CHLORO 3 (2 CYCLOPROPYLETHYNYL) 3 HYDROXYINDOLIN 2 ONE; ANTIRETROVIRUS AGENT; DELAVIRDINE; EFAVIRENZ; ISATIN; ISATIN DERIVATIVE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; DRUG PURIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION;

ANTI-HIV AGENTS; BENZOXAZINES; CELL LINE; CELL SURVIVAL; DRUG DESIGN; HIV REVERSE TRANSCRIPTASE; HUMANS; INDOLES; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 37349049277     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340607782360326     Document Type: Article

References (39)

1. Balzarini, J. Biochem. Pharmacol., 1999, 58, 1.
2. De Clercq, E. Il Farmaco, 1999, 54, 26.
3. Young, S. D.; Britcher, S. F.; Tran, L. O.; Payne, L. S.; Lumma, W. C.; Lyle, T. A.; Huff, J. R.; Anderson, P. S.; Olsen, D. B.; Carroll, S. S.; Pettibone, D. J.; O' brien, J. A.; Ball, R. G.; Balani, S. K.; Long, W. J.; Byrnes, V. W.; Emini, E. A. Antimicrob. Agents Chemother., 1995, 39, 2602.
4. Ptak, R. G. Expert Opin. Investig. Drugs, 2000, 11(8), 1099.
5. De Clercq, E. Nat. Rev. Drug. Discov., 2002, 1(1), 13.
6. Mansky, L. M.; Le Rouzic, E.; Benichou, S.; Gajary, L. C. J. Virol., 2003, 77(3), 2071.
7. (a) Silva, J. F. M.; Garden, S. J.; Pinto, A. C. J. Braz. Chem. Soc., 2001, 12, 3, 273;
8. (b) Boechat, N.; Pinto, A. C. 2000, US 6034266 A 20000307 CAN 132:194195 AN 2000:157748.
9. Sriram, D.; Bal, T. R.; Yogeeswari, P. J. Pharm. Pharmaceut. Sci., 2005, 8, 565.
10. Sriram, D.; Bal, T. R.; Yogeeswari, P. Farmaco, 2005, 60, 377.
11. Sriram, D.; Bal, T. R.; Yogeeswari, P. Med. Chem., 2005, 1, 277.
12. Sriram, D.; Bal, T. R.; Meena, K. Pharmazie, 2006, 61, 274.
13. (a) Pindur, U.; Adam, R. J. Heterocycl. Chem., 1988, 25, 1;
14. (b) Gribble, G. W. Contemp. Org. Syn., 1994, 1, 145;
15. (c) Furstner, A.; Bogdanovic, B. Angew. Chem. Int. Ed. Engl., 1996, 35, 2442;
16. (d) Sundberg, R. J. Indoles, Academic Press: San Diego, 1996; Vol. 1.
17. Keller, P.A.; Birch, C.; Leach, S.P.; Tyssen, D.; Griffith, R. J. J. Mol. Graphics Model., 2003, 21, 365.
18. a) Maginnity, P. M.; Gaulin, C. A. J. Am. Chem. Soc., 1951, 73, 3579.
19. b) Sumpter, W. C.; Jones, W. F. J. Am. Chem. Soc., 1943, 65, 1802.
20. c) Holt, J. S.; Kollie, A. E.; O'Sulivan, D. G.; Sadler, P. W. J. Chem. Soc., 1958, 1217.
21. d) Huntress, E. H.; Bornstein, J. J. Am. Chem. Soc., 1949, 71, 745.
22. e) Giovannini, E.; Potmann, P.; Jehl, A.; Schnyder, K.; Knecht, B.; Zen-Ruflinen, H. P. Helv. Chim. Acta, 1957, 249.
23. Alam, M.; Youmas, M.; Zafar, M. A.; Naeem, P. J. Sci. Ind. Res., 1989, 32, 246.
24. Garden, S. J.; Torres, J. C.; Silva, L. E.; Pinto, A. C. Synth. Commun., 1998, 28, 1679.
25. Frantz, D. E.; Fässler, R.; Tomooka, C. S.; Carreira, E. M. Acc. Chem. Res., 2000, 33, 373.
26. Jiang, B.; Feng, Y. Tetrahedron Lett., 2002, 43, 2975.
27. Pierce, M. E.; Parsons, R. L. Jr.; Radesca, L. A.; Lo, Y. S.; Silverman, S.; Moore, J. R.; Islam, Q.; Choudhury, A.; Fortunak, J. M. D.; Nguyen, D.; Luo, C.; Morgan, S. J.; Davis, W. P.; Confalone, P. N.; Chen, C.; Tillyer, R. D.; Frey, L.; Tan, L.; Xu, F.; Zhao, D.; Thompson, A. S.; Corley, E. G.; Grabowski, E. J. J.; Reamer, R.; Reider, P. J. J. Org. Chem., 1998, 63, 8536.
28. SYBYL 6.8 ed., Tripos Inc., 1699 South Hanley Rd., St. Louis, Missouri, 63144, USA; http://www.tripos.com.
29. Clark, M.; Cramer III, R. D.; Van Opdenbosch, N. J. Comp. Chem., 1989, 10, 982.
30. Ren, J.; Milton, J.; Weaver, K. L.; Short, S. A.; Stuart, D. I.; Stammers, D. K. Structure, 2000, 8, 1089.
31. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. Nucleic Acids Res., 2000, 28, 235.
32. Lipínski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Adv. Drug Deliv. Rev., 1997, 23, 3.
33. Ooms, F. Curr. Med. Chem., 2000, 7, 141.
34. Gasteiger, J.; Marsili, M. Tetrahedron, 1980, 36, 3219.
35. Chow, J.; Jurs, P. J. Chem. Inf. Comput. Sci., 1979, 19, 172.
36. Albert, J.; Bjoerling, E.; Von Gegerfelt, A.; Scarlatti, G.; Thorstensson, R.; Zhang, Y.; Fenyoe, E. M. AIDS Res. Hum. Retroviruses, 1993, 9, 501.
37. WHO-UNAIDS HIV-1 Vaccine Initiative, Initiative for Vaccine Research, Health Technology and Pharmaceutical, World Health Organization. WHO-UNAIDS Guidelines for Standard HIV Isolation and Characterization Procedures, 2002; 2 ed.
38. Bongertz, V.; Costa, C. I.; Guimarães, M. L.; Grinsztejn, B. Scand. J. Immunol., 1998, 47, 603.
39. Lindl, T.; Lewandowski, B.; Schreyogg, S.; Staudte, A. Altern. Lab. Anim., 2005, 33, 591.